HIV virus. Image produced from an image taken with transmission electron microscopy. Viral diameter around 110 to 125 nm.
BSIP/Universal Images

Biotech firm Moderna recently announced that it would never enforce the patent on its COVID-19 vaccine in 92 countries currently receiving the shots through a global program. It’s the first major pharmaceutical company to announce such a move, which critics say came later than it should have and which opens the door to wide-scale global production. Under CEO Stéphane Bancel, Moderna is also developing mRNA vaccines targeting 15 pathogens that are more common in the developing world, as well as longtime public-health threats such as influenza and RSV.

A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.

More Must-Reads From TIME

Contact us at